Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

CABOZANTINIB for Thyroid cancer: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 125 adverse event reports in the FDA FAERS database where CABOZANTINIB was used for Thyroid cancer.

Most Reported Side Effects for CABOZANTINIB

Side Effect Reports % Deaths Hosp.
Diarrhoea 404 10.6% 71 263
Fatigue 263 6.9% 70 175
Malignant neoplasm progression 238 6.2% 143 132
Nausea 215 5.6% 56 157
Decreased appetite 191 5.0% 44 133
Off label use 190 5.0% 71 76
Hypertension 165 4.3% 14 105
Pyrexia 162 4.2% 24 154
Vomiting 157 4.1% 46 127
Asthenia 153 4.0% 36 105
Death 153 4.0% 153 47
Palmar-plantar erythrodysaesthesia syndrome 144 3.8% 24 85
Dyspnoea 143 3.7% 40 125
Sepsis 130 3.4% 44 121
Stomatitis 126 3.3% 19 84

Other Indications for CABOZANTINIB

Renal cell carcinoma (1,241) Hepatocellular carcinoma (437) Metastatic renal cell carcinoma (292) Hormone-refractory prostate cancer (170) Transitional cell carcinoma (136) Non-small cell lung cancer (101) Product used for unknown indication (94) Renal cancer (77) Medullary thyroid cancer (73) Osteosarcoma (67)

Other Drugs Used for Thyroid cancer

LENVATINIB (2,668) CABOZANTINIB S-MALATE (1,615) VANDETANIB (591) DABRAFENIB (583) TRAMETINIB DIMETHYL SULFOXIDE (482) SORAFENIB (399) LEVOTHYROXINE (299) PAZOPANIB (264) PRALSETINIB (199) VEMURAFENIB (119)

Related Pages

CABOZANTINIB Full Profile All Thyroid cancer Drugs CABOZANTINIB Demographics CABOZANTINIB Timeline